Overview
Chronic pharyngitis (CP) is a persistent inflammatory condition affecting the pharyngeal mucosa, submucosa, and lymphoid tissues, leading to recurrent discomfort and functional impairment. Characterized by symptoms such as pharyngeal discomfort, foreign body sensation, and occasional cough, CP often results from unresolved acute infections, particularly those caused by Group A Streptococcus (GAS), which precede the chronic state in 56–97% of cases [PMID:34234411]. The chronic nature of this condition not only perpetuates symptoms but also poses long-term risks, including potential carcinogenesis due to persistent inflammation [PMID:32859182]. Epidemiologically, CP affects a significant portion of the adult population, with estimates ranging from 10-12% of pharyngeal diseases globally and up to 20% of adults experiencing symptoms [PMID:34707348]. High-income countries report substantial healthcare utilization, with millions of outpatient visits annually attributed to chronic pharyngitis, underscoring its substantial public health impact [PMID:32859182]. Environmental factors, such as passive smoking and pollution, further exacerbate the condition, highlighting the multifaceted nature of its etiology and management [PMID:22275918].
Pathophysiology
Chronic pharyngitis (CP) is fundamentally characterized by persistent inflammation that extends beyond the superficial mucosa to involve the submucosa and lymphoid tissues of the pharynx [PMID:34707348]. This chronic inflammatory state often originates from unresolved acute infections, particularly those caused by Group A Streptococcus (GAS), which are implicated in the majority of cases (56–97%) [PMID:34234411]. Persistent inflammation not only sustains the disease but also compromises the integrity of the nasopharyngeal mucosa, potentially leading to serious long-term complications, including an increased risk of carcinogenesis [PMID:32859182]. Metabolic profiling studies have revealed significant differences between healthy and CP states, suggesting that metabolic dysregulation plays a role in the disease process and may offer novel therapeutic targets [PMID:41946237]. Transcriptomic and metabolomic analyses have further elucidated the involvement of key signaling pathways such as PI3K/Akt and MAPK, which are critical in CP pathophysiology [PMID:41654072]. Compounds like Zhushagen-Shandougen have been shown to modulate these pathways, indicating their potential therapeutic value by suppressing pro-inflammatory mediators [PMID:41654072]. Additionally, fractions from herbs such as HPB and HPC have demonstrated efficacy in inhibiting key inflammatory proteins like PI3K, Akt1, JAK1, STAT3, MAPKs, and NF-κB, suggesting a multifaceted approach to managing inflammation in CP [PMID:39952902]. The role of atypical pathogens, such as Chlamydia pneumoniae, has also been explored, with studies indicating an association between IgA antibodies to C. pneumoniae and CP, pointing to the importance of considering atypical organisms in the differential diagnosis and treatment strategies [PMID:22886080].
Epidemiology
Chronic pharyngitis (CP) exhibits a high incidence rate, affecting approximately 10-12% of pharyngeal diseases and constituting a significant portion of otorhinolaryngology clinic visits [PMID:34707348]. Globally, at least 20% of adults suffer from CP, with substantial variations observed across different regions [PMID:34234411]. In high-income countries, CP accounts for a considerable burden on healthcare systems, with outpatient visits ranging from 7,000,000 to 11,000,000 annually in the United States alone [PMID:32859182]. In China, the incidence is particularly high, with studies reporting an incidence rate of up to 78.65% in examined populations, underscoring its significant public health impact [PMID:31091759]. Economic implications are also notable, with productivity losses and healthcare costs amounting to substantial figures—for instance, £400 million annually in the UK due to pharyngeal pain-related absenteeism [PMID:32791655]. Environmental factors, such as passive smoking, significantly influence CP prevalence, with studies showing an odds ratio of 16.7 for chronic pharyngitis among passive smokers in Congolese school children [PMID:22275918]. These epidemiological insights highlight the need for comprehensive preventive measures and targeted interventions to mitigate the widespread impact of CP.
Clinical Presentation
Patients with chronic pharyngitis (CP) typically present with a constellation of symptoms that significantly affect their quality of life. Common complaints include a persistent foreign body sensation in the throat, burning discomfort, and dysphonia (speech disorder), often accompanied by reduced auditory acuity [PMID:31091759]. Additional symptoms frequently reported are pharyngeal irritation, dryness, and chronic cough, which can be exacerbated by environmental factors such as passive smoking [PMID:22275918]. Morphologically, CP manifests with characteristic changes in the pharyngeal mucosa, including keratinization, hyperplasia of the epithelial layer, and inflammatory cell infiltration, which can lead to mucosal bleeding and ulceration [PMID:34091181]. These pathological alterations are often observed and assessed through pharyngoscopy, where clinical improvements correlate with reductions in inflammatory manifestations [PMID:29956507]. The comprehensive clinical evaluation typically encompasses six primary symptoms: severity of throat itching, hoarseness, pain, difficulty swallowing (odynophagia), cough, and ear pain (otalgia) [PMID:29146495]. These symptoms collectively reflect the multifaceted impact of chronic inflammation on the pharyngeal tissues and surrounding structures.
Diagnosis
Diagnosing chronic pharyngitis (CP) can be challenging due to overlapping symptoms with other conditions such as chronic tonsillitis, laryngitis, and even malignancies of the pharynx and larynx [PMID:31091759]. Clinical diagnosis based solely on medical history and physical examination has a positive predictive value limited to around 75%, necessitating more robust diagnostic approaches [PMID:31091759]. Recent advancements in diagnostic methodologies include the application of machine learning techniques, particularly through speech disorder analysis, which offers a preliminary and cost-effective diagnostic tool compared to traditional imaging methods like computed tomography [PMID:31091759]. Metabolomic profiling has also emerged as a promising diagnostic avenue, identifying distinct metabolic signatures that differentiate CP from healthy states [PMID:41946237]. Biomarker analysis further aids in diagnosis, with pro-inflammatory cytokines such as IL-1β, IL-6, PGE2, and TNF-α serving as potential indicators of disease activity and treatment efficacy [PMID:41654072]. Serological tests, including ELISA for IgA and IgG antibodies against Chlamydia pneumoniae, have shown significant associations with CP, providing additional diagnostic markers [PMID:22886080]. PCR and immunohistochemistry techniques for detecting C. pneumoniae in mucosal biopsies offer precise diagnostic tools, enhancing the accuracy of identifying underlying pathogens [PMID:9571739]. These evolving diagnostic strategies aim to improve early and accurate identification of CP, facilitating timely intervention.
Differential Diagnosis
Differentiating chronic pharyngitis (CP) from other conditions can be complex due to overlapping symptoms and clinical presentations. Common differential diagnoses include chronic tonsillitis, chronic laryngitis, pharyngeal and laryngeal tumors, and cervical spondylosis [PMID:31091759]. Chronic tonsillitis often presents with similar throat discomfort and recurrent infections, while chronic laryngitis may manifest with hoarseness and vocal changes, complicating the clinical picture [PMID:31091759]. Pharyngeal and laryngeal malignancies can present with persistent throat pain, dysphagia, and unexplained weight loss, requiring thorough endoscopic evaluations to rule out malignancy [PMID:31091759]. Cervical spondylosis, characterized by neck pain radiating to the throat, can also mimic CP symptoms, necessitating careful neurological and musculoskeletal assessments [PMID:31091759]. Additionally, while studies have ruled out significant roles for Fusobacterium spp and Mycoplasma pneumoniae in CP, atypical pathogens like Chlamydia pneumoniae remain under investigation, emphasizing the need for comprehensive microbiological evaluations [PMID:22886080]. Accurate differentiation relies on a combination of clinical history, physical examination, and targeted diagnostic tests to ensure appropriate management and avoid misdiagnosis.
Management
The management of chronic pharyngitis (CP) often faces challenges due to the limitations of conventional treatments such as broad-spectrum antibiotics and corticosteroids, which can lead to antibiotic resistance, recurrence, and significant side effects [PMID:34707348]. Traditional Western approaches, including the use of antibiotics and hormone preparations like dexamethasone, have shown efficacy but are constrained by issues such as narrow therapeutic spectra and adverse reactions [PMID:34707348]. In contrast, traditional Chinese medicine (TCM) offers promising alternatives with fewer side effects. For instance, YOL, a formulation containing honeysuckle, scutellaria, bupleurum, and cicada, effectively alleviates pharyngeal pain and treats upper respiratory tract infections with minimal toxicity [PMID:34707348]. Compound Herba Sarcandrae (FFZJF) has demonstrated anti-inflammatory and antibacterial properties, making it a viable option with minimal side effects, particularly in reducing reliance on antibiotics [PMID:34234411]. Ganluyin (GLY), a blend of ten traditional Chinese medicines, has shown significant anti-inflammatory effects and protective benefits against throat inflammation, potentially offering a safer therapeutic alternative to conventional medications [PMID:32859182]. Specific components within GLY, such as DOP and Ophiopogon japonicus, contribute to immunomodulatory and analgesic effects, enhancing overall treatment efficacy [PMID:32859182]. Natural therapies like Banxia-Houpo-Tang (BHT), comprising herbs such as Pinellia ternata and Magnolia, are being explored for their efficacy and safety, providing additional options for managing CP [PMID:32791655]. Additionally, pharmacological interventions targeting key inflammatory pathways, such as the TLR4/NF-κB pathway (DOFP) and PI3K/Akt and MAPK pathways (Zhushagen-Shandougen), have shown promise in reducing inflammation and improving clinical outcomes in animal models [PMID:39067830, PMID:41654072]. These multifaceted approaches aim to address both the inflammatory burden and potential long-term complications associated with CP.
Complications
Chronic pharyngitis (CP) is not only characterized by persistent symptoms but also carries the risk of several complications that can significantly impact patient health. Environmental factors, particularly pollution, play a crucial role in exacerbating CP, with studies indicating a high prevalence of 81.9% in urban residents from severely polluted areas [PMID:32859182]. This environmental influence underscores the importance of considering environmental exposures in managing CP. Metabolomic analyses have revealed involvement in pathways such as riboflavin and glutathione metabolism, suggesting that oxidative stress and immune dysregulation may underlie these complications [PMID:41654072]. For instance, compromised mucosal barrier function, often associated with increased inflammation, can lead to secondary infections and further tissue damage. DOFP (Deapio-platycodin E) has shown potential in mitigating these complications by repairing the intestinal barrier and modulating inflammatory markers like TNF-α and IL-1β, thereby reducing excessive mucus secretion and inflammation [PMID:39067830]. These findings highlight the need for comprehensive management strategies that address not only the primary symptoms but also the underlying mechanisms contributing to long-term complications, potentially reducing the risk of more severe health issues.
Prognosis & Follow-up
The prognosis of chronic pharyngitis (CP) varies based on the effectiveness of management strategies and individual patient factors. Pathology analyses in animal models treated with compounds like PCG (Polygonum cuspidatum glycoside) have shown dose-dependent reductions in pathologic cellular changes, suggesting a positive impact on symptom management and long-term outcomes [PMID:29146495]. Regular follow-up is crucial for monitoring disease progression and treatment efficacy. Clinical assessments should include periodic evaluations of key symptoms such as throat discomfort, hoarseness, and difficulty swallowing, alongside biomarker monitoring, particularly pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α, which can indicate disease activity and response to therapy [PMID:41654072]. Additionally, imaging and endoscopic evaluations can help track morphological changes in the pharyngeal mucosa, ensuring that interventions are effectively mitigating inflammatory manifestations and preventing complications. Long-term management often requires a multidisciplinary approach, integrating pharmacological treatments with lifestyle modifications and environmental controls to optimize patient outcomes and reduce recurrence rates.
Special Populations
In managing chronic pharyngitis (CP) among special populations, traditional Chinese medicine (TCM) formulations like YOL emerge as particularly valuable due to their safety profile and minor toxic side effects [PMID:34707348]. These formulations, comprising herbs such as honeysuckle, scutellaria, bupleurum, and cicada, offer a gentler yet effective approach compared to conventional Western medications, which can have significant side effects. This makes TCM an attractive option for sensitive populations, including children, elderly patients, and those with compromised immune systems, where minimizing adverse reactions is paramount. Additionally, pregnant women and individuals with pre-existing conditions may benefit from the targeted anti-inflammatory and immunomodulatory effects provided by TCM, ensuring a safer therapeutic environment without compromising efficacy. Tailored management strategies that consider these populations' unique needs can significantly enhance treatment outcomes and quality of life.
Key Recommendations
These recommendations aim to provide a holistic framework for managing chronic pharyngitis, integrating evidence-based practices with innovative therapeutic approaches to improve patient outcomes and quality of life.
References
1 Ji S, Xu F, Zhu R, Wang C, Guo D, Jiang Y. Mechanism of Yinqin Oral Liquid in the Treatment of Chronic Pharyngitis Based on Network Pharmacology. Drug design, development and therapy 2021. link 2 Zhang Y, Yuan T, Li Y, Wu N, Dai X. Network Pharmacology Analysis of the Mechanisms of Compound Herba Sarcandrae (Fufang Zhongjiefeng) Aerosol in Chronic Pharyngitis Treatment. Drug design, development and therapy 2021. link 3 Chen YH, Luo R, Lei SS, Li B, Zhou FC, Wang HY et al.. Anti-inflammatory effect of Ganluyin, a Chinese classic prescription, in chronic pharyngitis rat model. BMC complementary medicine and therapies 2020. link 4 Xu C, Yue R, Lv X, Wu T, Yang M, Chen Y. The efficacy and safety of Banxia-Houpo-Tang for chronic pharyngitis: A protocol for systematic review and meta analysis. Medicine 2020. link 5 Li Z, Huang J, Hu Z. Screening and Diagnosis of Chronic Pharyngitis Based on Deep Learning. International journal of environmental research and public health 2019. link 6 Gedikondele JS, Longo-Mbenza B, Nzanza JM, Luila EL, Reddy P, Buso D. Nose and throat complications associated with passive smoking among Congolese school children. African health sciences 2011. link 7 Wang X, Chen Y, Wang W, Luo L, Bai Z, Li K et al.. Metabolism and efficacy-oriented screening of Q-markers for platycodon grandiflorum: A comprehensive evaluation framework of inflammation-specific metabolites and pharmacologically active components in chronic pharyngitis treatment. Journal of pharmaceutical and biomedical analysis 2026. link 8 Chen Y, Shi H, Yang ZJ, Liu XW, Li-Yan Zhang, Dong X et al.. Integrating transcriptomics and metabolomics to explore the therapeutic effects and mechanisms of Zhushagen-Shandougen herb pair on chronic pharyngitis. Journal of ethnopharmacology 2026. link 9 Li X, Wang J, Liang J, He J, Cao L, Yang L. Hosta plantaginea Flower Ameliorates Chronic Pharyngitis by Suppressing Inflammation via the JAK-STAT/PI3K/MAPK Signaling Axis in Rats. Chemistry & biodiversity 2025. link 10 Yan M, Tian Y, Fu M, Zhou H, Yu J, Su J et al.. Polysaccharides, the active component of Dendrobiumofficinale flower, ameliorates chronic pharyngitis in rats via TLR4/NF-κb pathway regulation. Journal of ethnopharmacology 2024. link 11 Ran F, Han X, Deng X, Wu Z, Huang H, Qiu M et al.. High or low temperature extraction, which is more conducive to Triphala against chronic pharyngitis?. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021. link 12 Shakhova M, Loginova D, Meller A, Sapunov D, Orlinskaya N, Shakhov A et al.. Photodynamic therapy with chlorin-based photosensitizer at 405 nm: numerical, morphological, and clinical study. Journal of biomedical optics 2018. link 13 Chen L, Lai Y, Dong L, Kang S, Chen X. Polysaccharides from Citrus grandis L. Osbeck suppress inflammation and relieve chronic pharyngitis. Microbial pathogenesis 2017. link 14 Naina P, Anandan S, Mathews SS, Job A, Albert RR. Chronic pharyngitis: role of atypical organisms: a case control study from South India. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2012. link 15 Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W et al.. Experimental investigation of the immunoregulatory and anti-inflammatory effects of the traditional Chinese medicine "Li-Yan Zhi-Ke Granule" for relieving chronic pharyngitis in rats. Molecular biology reports 2011. link 16 Falck G, Engstrand I, Gad A, Gnarpe J, Gnarpe H, Laurila A. Demonstration of Chlamydia pneumoniae in patients with chronic pharyngitis. Scandinavian journal of infectious diseases 1997. link 17 Li Y. The relationship between SIgA and chronic granular pharyngitis. The Journal of laryngology and otology 1993. link
17 papers cited of 18 indexed.